Follow us:Follow Us on Twitter Like Us on Facebook Follow Us on Google+ Watch videos on our Youtube channel
- Myocardial infarction
ALLogeneic heart STem cells to Achieve myocardial Regeneration, ALLSTAR
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction
This study is to determine the safety profile and evaluate whether CAP-1002 (heart stem cells) administered into the heart of patients with inadequate blood supply (ischemic left ventricular dysfunction) and a previous heart attack (anterior myocardial infarction (MI)) may result in structural cardiac or functional clinical benefits for patients.
More medical summary: This study is to determine the safety profile and evaluate whether CAP-1002 (heart stem cells) administered by intracoronary infusion in patients with ischemic left ventricular dysfunction and a previous anterior myocardial infarction (MI) may result in structural cardiac or functional clinical benefits for patients.
Raj Makkar, MD
Hasanian Al-Jilaihawi, MD
Jorge Castellanos, MD
Abhijeet Dhoble, MD
Timothy Henry, MD
Mamoo Nakamura, MD
Study Coordinator and Contact:
Tracey S. Early, BS, MA, CCRP